It is proposed that abnormal activity of hepatic signaling pathways involving FTO links metabolic impairments such as obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). This evidence concerns the gene FTO and obesity due to melanocortin 4 receptor deficiency.